One_CD day_NN at_IN a_DT time_NN Small_JJ changes_NNS count_NN ._.
Twenty_CD years_NNS ago_RB ,_, GSK_NNP servant_NN Daniel_NNP Calleja_NNP takes_VBZ life_NN scientist_NN Steve_NNP Smith_NNP started_VBD a_DT journey_NN one_CD day_NN at_IN a_DT time_NN following_VBG his_PRP$ that_WDT would_MD lead_VB to_TO the_DT successful_JJ diagnosis_NN as_IN a_DT diabetic_NN some_DT 21_CD development_NN of_IN Avandia_NNP ,_, our_PRP$ years_NNS ago_RB ._.
Type_NN 2_CD diabetes_NN has_VBZ led_VBN treatment_NN for_IN type_NN 2_CD diabetes_NN ._.
It_PRP was_VBD to_TO him_PRP having_VBG to_TO make_VB a_DT number_NN of_IN to_TO be_VB a_DT meticulous_JJ ,_, step-by-step_JJ ,_, small_JJ changes_NNS in_IN his_PRP$ lifestyle_NN -_: but_CC pioneering_JJ path_NN ._.
he_PRP still_RB retains_VBZ a_DT mischievous_JJ sense_NN There_EX was_VBD limited_VBN understanding_NN of_IN of_IN humor_NN and_CC sprinkles_VBZ his_PRP$ conversation_NN diabetes_NN and_CC insulin_NN resistance_NN in_IN 1984_CD with_IN jokes_NNS ._.
when_WRB Steve_NNP and_CC his_PRP$ team_NN in_IN the_DT UK_NNP During_IN his_PRP$ daily_JJ stints_NNS on_IN the_DT exercise_NN started_VBD the_DT painstaking_NN search_NN for_IN bike_NN at_IN his_PRP$ home_NN in_IN Spain_NNP ,_, he_PRP imagines_VBZ compounds_NNS ._.
We_PRP were_VBD able_JJ to_TO test_VB just_RB he_PRP is_VBZ one_CD of_IN the_DT star_NN cyclists_NNS at_IN the_DT head_NN two_CD or_CC three_CD compounds_NNS a_DT week_NN ,_, while_IN of_IN the_DT race_NN ._.
I_PRP never_RB win_VBP but_CC I_PRP can_MD todays_VB high_JJ throughput_NN screening_NN can_MD always_RB dream_VB ,_, says_VBZ the_DT 75-year_JJ old_JJ ._.
probably_RB test_NN one_CD million_CD in_IN a_DT few_JJ Daniels_NNP mother_NN and_CC father_NN both_DT had_VBD days_NNS ,_, he_PRP said_VBD ._.
diabetes_NN so_IN he_PRP was_VBD not_RB surprised_VBN when_WRB ,_, It_PRP took_VBD four_CD years_NNS of_IN methodical_JJ after_IN developing_VBG symptoms_NNS ,_, his_PRP$ disease_NN searching_VBG before_IN a_DT promising_JJ compound_NN was_VBD diagnosed_VBN ._.
Initially_RB ,_, Daniel_NNP found_VBD it_PRP was_VBD identified_VBN ._.
It_PRP was_VBD a_DT discovery_NN made_VBD difficult_JJ to_TO control_VB his_PRP$ blood_NN sugar_NN level_NN largely_RB through_IN the_DT teams_NNS innovative_JJ but_CC three_CD years_NNS ago_IN he_PRP started_VBD to_TO use_VB use_NN of_IN chemistry_NN in_IN manipulating_VBG the_DT Avandia_NNP and_CC quickly_RB noticed_VBD an_DT structure_NN of_IN molecules_NNS ,_, yet_CC it_PRP was_VBD just_RB a_DT improvement_NN ._.
start_NN in_IN the_DT lengthy_JJ process_NN of_IN bringing_VBG As_IN a_DT result_NN of_IN my_PRP$ age_NN ,_, I_PRP had_VBD reached_VBN Avandia_NNP to_TO market_NN ._.
the_DT point_NN where_WRB my_PRP$ sugars_NNS were_VBD getting_VBG The_DT application_NN to_TO the_DT FDA_NNP in_IN 1998_CD out_IN of_IN control_NN and_CC insulin_NN injections_NNS came_VBD with_IN a_DT dossier_NN that_WDT was_VBD one_CD of_IN seemed_VBN inevitable_JJ ,_, he_PRP recalls_VBZ ._.
My_PRP$ the_DT largest_JJS in_IN the_DT industry_NN ._.
Avandia_NNP was_VBD doctor_NN prescribed_VBN Avandia_NNP ,_, however_RB ,_, launched_VBD the_DT following_JJ year_NN in_IN the_DT USA_NNP and_CC now_RB I_PRP have_VBP better_JJR control_NN over_IN my_PRP$ where_WRB the_DT Avandia_NNP product_NN family_NN leads_VBZ blood_NN sugar_NN level_NN than_IN before_RB ._.
Daniel_NNP has_VBZ also_RB taken_VBN other_JJ steps_NNS Recently_RB launched_VBD was_VBD Avandamet_NNP ,_, along_IN the_DT path_NN to_TO maintaining_VBG his_PRP$ good_JJ the_DT first_JJ drug_NN to_TO combine_VB an_DT insulin_NN health_NN ._.
In_IN addition_NN to_TO a_DT daily_JJ session_NN on_IN sensitiser_NN Avandia_NNP with_IN another_DT his_PRP$ exercise_NN bike_NN ,_, he_PRP also_RB walks_VBZ for_IN an_DT treatment_NN to_TO help_VB control_VB blood_NN sugar_NN hour_NN a_DT day_NN near_IN his_PRP$ home_NN in_IN Madrid_NNP ._.
Avandaryl_NNP ,_, a_DT new_JJ fixed-dose_JJ As_IN for_IN the_DT future_NN ,_, I_PRP hope_VBP I_PRP can_MD go_VB on_IN combination_NN treatment_NN filed_VBN with_IN the_DT like_IN this_DT forever_RB ._.
Certainly_RB ,_, as_IN far_RB as_IN my_PRP$ FDA_NNP in_IN 2003_CD ,_, is_VBZ the_DT latest_JJS step_NN in_IN the_DT diabetes_NN is_VBZ concerned_VBN ,_, I_PRP can_MD live_VB journey_NN that_WDT began_VBD in_IN 1984_CD ._.
perfectly_RB well_RB with_IN it_PRP ._.
Steve_NNP and_CC his_PRP$ team_NN won_VBD a_DT UK_NNP drug_NN discovery_NN award_NN for_IN biology_NN and_CC chemistry_NN in_IN the_DT work_NN on_IN Avandia_NNP ._.
Scientists_NNS were_VBD methodical_JJ yesterday_NN and_CC remain_VBP so_RB today_NN ,_, but_CC we_PRP also_RB need_VBP inspiration_NN ,_, to_TO take_VB risks_NNS ..._: and_CC have_VBP some_DT luck_NN ._.
06_CD Annual_JJ Review_NNP 2003_CD Annual_JJ Review_NNP 2003_CD 07_CD The_DT day_NN my_PRP$ life_NN changed_VBD Working_JJ together_RB ._.
Sprightly_RB senior_JJ Making_VBG life_NN easier_JJR ._.
GSK_NNP seeks_VBZ to_TO play_VB an_DT active_JJ part_NN in_IN improving_VBG the_DT healthcare_NN of_IN people_NNS John_NNP Chicoine_NNP wasnt_NN sure_JJ what_WP to_TO who_WP have_VBP limited_VBN access_NN to_TO medicines_NNS ,_, not_RB only_RB those_DT in_IN developing_VBG countries_NNS ._.
Our_PRP$ Orange_NNP Card_NNP think_VBP when_WRB he_PRP left_VBD his_PRP$ local_JJ store_NN in_IN program_NN has_VBZ helped_VBN more_JJR than_IN 150,000_CD senior_JJ American_JJ citizens_NNS on_IN low_JJ incomes_NNS to_TO save_VB on_IN the_DT North_NNP Carolina_NNP in_IN the_DT USA_NNP after_IN medicines_NNS they_PRP buy_VBP ._.
In_IN 2003_CD ,_, GSK_NNP reinforced_VBD its_PRP$ commitment_NN to_TO this_DT program_NN until_IN at_IN least_JJS 2006_CD ._.
using_VBG his_PRP$ Together_RB Rx_NNP Card_NNP for_IN the_DT first_JJ time_NN ._.
He_PRP had_VBD just_RB obtained_VBN two_CD prescription_NN medicines_NNS for_IN $_$ 30_CD which_WDT in_IN the_DT past_NN would_MD have_VB cost_VBN him_PRP $_$ 140_CD ._.
I_PRP couldnt_VBP believe_VB it_PRP and_CC went_VBD and_CC told_VBD Card_NNP savings_NNS Following_VBG positive_JJ responses_NNS my_PRP$ wife_NN Jackie_NNP that_IN I_PRP had_VBD just_RB robbed_VBN The_DT Orange_NNP Card_NNP was_VBD announced_VBN to_TO the_DT Orange_NNP Card_NNP ,_, GSK_NNP and_CC six_CD Leading_JJ role_NN Wal-Mart_NNP ._.
When_WRB we_PRP thought_VBD about_RB in_IN late_JJ 2001_CD in_IN response_NN to_TO concerns_NNS other_JJ companies_NNS launched_VBD the_DT GSK_NNP plays_VBZ a_DT leading_JJ role_NN in_IN how_WRB much_JJ we_PRP had_VBD saved_VBN ,_, I_PRP suggested_VBD by_IN senior_JJ citizens_NNS in_IN the_DT USA_NNP about_IN Together_RB Rx_NNP Card_NNP in_IN 2002_CD ._.
This_DT improving_VBG access_NN to_TO medicines_NNS ._.
we_PRP get_VBP in_IN the_DT car_NN and_CC get_VB away_RB quickly_RB coverage_NN for_IN prescription_NN medicines_NNS ._.
brings_VBZ company-sponsored_JJ savings_NNS Through_IN product_NN ,_, pricing_NN and_CC before_IN they_PRP caught_VBD us_PRP !_.
Because_IN Medicare_NNP does_VBZ not_RB cover_VB programs_NNS into_IN a_DT single_JJ card_NN ,_, partnership_NN programs_NNS ,_, GSK_NNP seeks_VBZ most_JJS prescription_NN drugs_NNS ,_, 10_CD to_TO 15_CD extending_VBG the_DT possible_JJ savings_NNS at_IN to_TO ensure_VB that_IN safe_JJ and_CC effective_JJ The_DT Together_RB Rx_JJ program_NN was_VBD launched_VBN million_CD senior_JJ Americans_NNS do_VBP not_RB the_DT pharmacy_NN counter_NN to_TO more_JJR than_IN drugs_NNS reach_VBP people_NNS who_WP need_VBP in_IN the_DT USA_NNP in_IN April_NNP 2002_CD with_IN the_DT have_VBP insurance_NN coverage_NN for_IN their_PRP$ 170_CD widely_RB prescribed_VBN medicines_NNS ._.
them_PRP most_RBS on_IN a_DT sustainable_JJ basis_NN ._.
potential_JJ to_TO allow_VB between_IN eight_CD and_CC 11_CD prescriptions_NNS ._.
million_CD Medicare_NNP enrolees_NNS with_IN no_DT Alongside_IN the_DT Orange_NNP Card_NNP With_IN this_DT easy-to-use_JJ card_NN ,_, Together_RB and_CC the_DT Together_RB Rx_NNP Card_NNP ,_, prescription_NN drug_NN coverage_NN to_TO be_VB eligible_JJ GSKs_NNP Orange_NNP Card_NNP ,_, the_DT industrys_NNS Rx_NN participants_NNS are_VBP able_JJ to_TO save_VB up_RP two_CD Patient_NNP Assistance_NNP for_IN a_DT broad_JJ range_NN of_IN medicines_NNS from_IN first_JJ senior_JJ savings_NNS prescription_NN to_TO 40_CD per_IN cent_NN off_IN the_DT usual_JJ amount_NN Programs_NNP Bridges_NNP to_TO Access_NNP major_JJ pharmaceutical_JJ companies_NNS ._.
In_IN the_DT drug_NN card_NN ,_, offers_VBZ average_JJ savings_NNS paid_VBN for_IN prescriptions_NNS -_: sometimes_RB and_CC Commitment_NNP to_TO Access_NNP past_NN ,_, many_JJ older_JJR Americans_NNPS with_IN little_JJ or_CC of_IN 30_CD per_IN cent_NN off_IN the_DT usual_JJ price_NN substantially_RB more_RBR ._.
By_IN the_DT end_NN of_IN provide_VB short-term_JJ solutions_NNS no_DT prescription_NN coverage_NN would_MD cut_VB back_RB for_IN outpatient_NN GSK_NNP prescription_NN 2003_CD ,_, approximately_RB 1.2_CD million_CD for_IN needy_JJ patients_NNS without_IN on_IN taking_VBG their_PRP$ recommended_VBN medicines_NNS ._.
Seniors_NNS simply_RB present_JJ people_NNS had_VBD joined_VBN this_DT program_NN ._.
prescription_NN drug_NN insurance_NN medications_NNS or_CC risk_VB their_PRP$ health_NN by_IN taking_VBG their_PRP$ card_NN to_TO the_DT pharmacist_NN to_TO coverage_NN ._.
In_IN 2003_CD ,_, there_EX GSK_NNP also_RB provides_VBZ reimbursement_NN were_VBD 155,000_CD members_NNS of_IN the_DT I_PRP am_VBP always_RB looking_VBG for_IN bargains_NNS and_CC case_NN management_NN services_NNS to_TO Orange_NNP Card_NNP program_NN ._.
looked_VBD at_IN several_JJ prescription_NN plans_NNS help_VBP patients_NNS identify_VB alternative_NN which_WDT ,_, when_WRB you_PRP looked_VBD closely_RB ,_, offered_VBD funding_NN sources_NNS for_IN prescription_NN GSK_NNP supports_VBZ comprehensive_JJ no_DT benefit_NN at_IN all_DT ,_, said_VBD John_NNP ._.
Then_RB I_PRP drugs_NNS and_CC other_JJ healthcare_NN reform_NN of_IN the_DT Medicare_NNP program_NN services_NNS ._.
found_VBN out_IN about_IN Together_RB Rx_NN while_IN in_IN the_DT USA_NNP ._.
In_IN 2003_CD ,_, the_DT company_NN flipping_VBG through_IN a_DT magazine_NN and_CC went_VBD reinforced_VBN its_PRP$ commitment_NN to_TO the_DT on-line_JJ to_TO find_VB out_RP more_RBR ._.
It_PRP was_VBD easy_JJ to_TO Orange_NNP Card_NNP scheme_NN until_IN at_IN least_JJS apply_VB and_CC the_DT benefits_NNS were_VBD instant_JJ ._.
2006_CD ,_, when_WRB a_DT new_JJ Medicare_NNP drug_NN benefit_NN is_VBZ expected_VBN ._.
